We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

bioMérieux has created a new Fungal Susceptibility Card for susceptibility testing of Candida species and Cryptococcus neoformans.

The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.

Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations.

Early diagnosis and prompt treatment are the key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardized and rapid yeast susceptibility testing.

The VITEK 2 AST-YS07 Fungal Susceptibility Card, which replaces VITEK 2 AST-YS06, complements the current antifungals - amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole - with micafungin, an echinocandin active against Candida species, further extending the capabilities of the VITEK 2 and helping to ensure that the correct treatment is swiftly initiated.